ROMO1 and colorectal carcinoma: Compared with controlled CRC cells, invasive activity decreased by approximately 51% in HCT116 transfected with Romo1 shRNA and approximately 42% in DLD-1 transfected with Romo1 siRNA (Fig 4C).